These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 27906468)

  • 1. Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list.
    Chhatwal J; Samur S; Kues B; Ayer T; Roberts MS; Kanwal F; Hur C; Donnell DM; Chung RT
    Hepatology; 2017 Mar; 65(3):777-788. PubMed ID: 27906468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost Effectiveness of Pre- vs Post-Liver Transplant Hepatitis C Treatment With Direct-Acting Antivirals.
    Samur S; Kues B; Ayer T; Roberts MS; Kanwal F; Hur C; Donnell DMS; Chung RT; Chhatwal J
    Clin Gastroenterol Hepatol; 2018 Jan; 16(1):115-122.e10. PubMed ID: 28634131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of patients waitlisted for liver transplant with all-oral direct-acting antivirals is a cost-effective treatment strategy in the United States.
    Ahmed A; Gonzalez SA; Cholankeril G; Perumpail RB; McGinnis J; Saab S; Beckerman R; Younossi ZM
    Hepatology; 2017 Jul; 66(1):46-56. PubMed ID: 28257591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temporal Changes and Regional Variation in Acceptance of Hepatitis C Virus-Viremic Livers.
    Mazur RD; Goldberg DS
    Liver Transpl; 2019 Dec; 25(12):1800-1810. PubMed ID: 31539195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing repeat liver transplant graft utility through strategic matching of donor and recipient characteristics.
    Hung K; Gralla J; Dodge JL; Bambha KM; Dirchwolf M; Rosen HR; Biggins SW
    Liver Transpl; 2015 Nov; 21(11):1365-73. PubMed ID: 25865434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list composition.
    Crespo G; Trota N; Londoño MC; Mauro E; Baliellas C; Castells L; Castellote J; Tort J; Forns X; Navasa M
    J Hepatol; 2018 Jul; 69(1):11-17. PubMed ID: 29481821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy.
    Flemming JA; Kim WR; Brosgart CL; Terrault NA
    Hepatology; 2017 Mar; 65(3):804-812. PubMed ID: 28012259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transplanting hepatitis C virus-positive livers into hepatitis C virus-negative patients with preemptive antiviral treatment: A modeling study.
    Chhatwal J; Samur S; Bethea ED; Ayer T; Kanwal F; Hur C; Roberts MS; Terrault N; Chung RT
    Hepatology; 2018 Jun; 67(6):2085-2095. PubMed ID: 29222916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in practice and perception of hepatitis C and liver transplantation: Results of a national survey.
    Shaffer AA; Thomas AG; Bowring MG; Van Pilsum Rasmussen SE; Cash A; Kucirka LM; Alqahtani SA; Gurakar A; Sulkowski MS; Cameron AM; Segev DL; Durand CM
    Transpl Infect Dis; 2018 Dec; 20(6):e12982. PubMed ID: 30144258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of liver transplantation waiting list for decompensated cirrhosis in a Spanish tertiary hospital: differences between hepatitis C virus recipients and other etiologies.
    Ibáñez Samaniego L; Pérez Valderas M; Fernández Yunquera A; Rincón Rodríguez D; López Baena JA; Matilla Peña A; Catalina Rodríguez MV; Clemente Ricote G; Bañares Cañizares R; Salcedo Plaza M
    Transplant Proc; 2014 Nov; 46(9):3084-6. PubMed ID: 25420829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pleasant dilemma to have: to treat the HCV patient on the waiting list or to treat post-liver transplantation?
    Barsa JE; Branch AD; Schiano TD
    Clin Transplant; 2015 Oct; 29(10):859-65. PubMed ID: 26329668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver transplant recipients and prioritization of anti-HCV therapy: an Italian cohort analysis.
    Lanini S; Nanni Costa A; Grossi PA; Procaccio F; Ricci A; Capobianchi MR; Terrault NA; Ippolito G
    Liver Int; 2016 Mar; 36(3):410-7. PubMed ID: 26264452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis.
    Njei B; McCarty TR; Fortune BE; Lim JK
    Aliment Pharmacol Ther; 2016 Nov; 44(10):1090-1101. PubMed ID: 27640785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list.
    Vitale A; Volk ML; De Feo TM; Burra P; Frigo AC; Ramirez Morales R; De Carlis L; Belli L; Colledan M; Fagiuoli S; Rossi G; Andorno E; Baccarani U; Regalia E; Vivarelli M; Donataccio M; Cillo U;
    J Hepatol; 2014 Feb; 60(2):290-7. PubMed ID: 24161408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals.
    Zanetto A; Shalaby S; Vitale A; Mescoli C; Ferrarese A; Gambato M; Franceschet E; Germani G; Senzolo M; Romano A; Angeli P; Rugge M; Farinati F; Forton DM; Cillo U; Burra P; Russo FP
    Liver Transpl; 2017 Sep; 23(9):1103-1112. PubMed ID: 28544587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival benefit of repeat liver transplantation in the United States: a serial MELD analysis by hepatitis C status and donor risk index.
    Biggins SW; Gralla J; Dodge JL; Bambha KM; Tong S; Barón AE; Inadomi J; Terrault N; Rosen HR
    Am J Transplant; 2014 Nov; 14(11):2588-94. PubMed ID: 25243648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective-prospective study of safety and efficacy of sofosbuvir-based direct-acting antivirals in HIV/HCV-coinfected participants with decompensated liver disease pre- or post-liver transplant.
    Peters MG; Kottilil S; Terrault N; Amara D; Husson J; Huprikar S; Florman S; Sulkowski MS; Durand CM; Luetkemeyer AF; Rogers R; Grab J; Haydel B; Blumberg E; Dove L; Emond J; Olthoff K; Smith C; Fishbein T; Masur H; Stock PG
    Am J Transplant; 2021 May; 21(5):1780-1788. PubMed ID: 33277801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved liver transplant waitlist mortality and lower risk of disease progression among chronic hepatitis C patients awaiting liver transplantation after the introduction of direct-acting antiviral therapies in the United States.
    Young K; Liu B; Bhuket T; Gish RG; Wong RJ
    J Viral Hepat; 2019 Mar; 26(3):350-361. PubMed ID: 30412318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation.
    Vitale A; Spolverato G; Burra P; De Feo TM; Belli L; Donato F; Baroni GS; Marianelli T; Picciotto A; Toniutto P; Bhoori S; Passigato N; Lucà MG; Russo FP; Cillo U; Fagiuoli S;
    Transpl Int; 2015 Sep; 28(9):1055-65. PubMed ID: 25865602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver transplantation for hepatitis C patients in the era of direct-acting antiviral treatment: A retrospective cohort study.
    Khan AS; Adams N; Vachharajani N; Dageforde L; Wellen J; Shenoy S; Crippin JS; Doyle MB; Chapman WC
    Int J Surg; 2020 Mar; 75():84-90. PubMed ID: 32014598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.